Press Release, Tauriga Sciences Inc. Commences 2nd and Much Larger Production Run of its Plant Based CBD Infused Gum Drop Product, Branded as: Tauri-Gummies.
NEW YORK, NY, May 15, 2020 (GLOBE NEWSWIRE) -- via NEWMEDIAWIRE -- Tauriga Sciences, Inc. (OTCQB: TAUG) (“Tauriga” or the “Company”), a revenue generating Company that operates through the development, distribution, and licensing of proprietary products as well as the evaluation of potential acquisition opportunities and equity investments, today announced that it has commenced its 2nd production run of its plant based Cannabidiol (“CBD”) infused Gum Drop product, branded as: Tauri-Gummies™. The initial production run was completed during January 2020, for a total of 1,000 Units (“Jar” or “Pack”). This 2nd production run, which is expected to be completed within the next 2-3 weeks, will yield a total of 2,200 Jars. Tauri-Gummies™ sales have been consistently strong on the Company’s E-Commerce platform (www.taurigum.com). Each Jar of the Company’s Tauri-Gummies™ product, has an established MSRP of $24.99.
The Company’s Tauri-Gummies™ product is Gelatin-Free and consists of 4 distinct Gum Drop flavors – Format: 1950s nostalgic style. These flavors are: Cherry (red), Orange (orange), Lemon (yellow), and Lime (green).
ABOUT TAURIGA SCIENCES INC.
Tauriga Sciences, Inc. (TAUG) is a revenue generating, diversified life sciences company, engaged in several major business activities and initiatives. The company manufactures and distributes several proprietary retail products and product lines, mainly focused on the Cannabidiol (“CBD”) and Cannabigerol (“CBG”) Edibles market segment. The main product line, branded as Tauri-Gum™, consists of a proprietary supplement chewing gum that is both Kosher certified and Vegan formulated (CBD Infused Tauri-Gum™ Flavors: Mint, Blood Orange, Pomegranate) & (CBG Infused Tauri-Gum™ Flavor: Peach-Lemon). The Company’s commercialization strategy consists of a broad array of retail customers, distributors, and a fast-growing E-Commerce business segment (E-Commerce website: www.taurigum.com). Please visit our corporate website, for additional information, as well as inquiries, at www.tauriga.com.
Complementary to the Company’s retail business, are its two ongoing biotechnology initiatives. The first one relates to the development of a Pharmaceutical grade version of Tauri-Gum™, for nausea regulation (specifically designed to help patients that are subjected to ongoing chemotherapy treatment). On March 18, 2020, the Company announced that it filed a provisional U.S. patent application covering its pharmaceutical grade version of Tauri-Gum™. The Patent, filed with the U.S.P.T.O. is Titled “MEDICATED CBD COMPOSITIONS, METHODS OF MANUFACTURING, AND METHODS OF TREATMENT”. The second one relates to a collaboration agreement with Aegea Biotechnologies Inc. for the co-development of a rapid, multiplexed, Novel Coronavirus (COVID-19) test with superior sensitivity and selectivity.
The Company is headquartered in New York City and operates a regional office in Barcelona, Spain. In addition, the Company operates a full time E-Commerce fulfillment center located in LaGrangeville, New York.